［1］ ZUBAIR H,KHAN MA,ANAND S,et al.Modulation of the tumor microenvironment by natural agents:implications for cancer prevention and therapy［J］.Semin Cancer Biol,2022,80:237-255.
［2］ LOW JY,BRENNEN WN,MEEKER AK,et al.Stromal CAVIN1 controls prostate cancer microenvironment and metastasis by modulating lipid distribution and inflammatory signaling［J］.Mol Cancer Res,2020,18(9):1414-1426.
［3］ MOTLAGH AL,MAHDAVI MA,LOSKOG A.The tumor microenvironment:a milieu hindering and obstructing antitumor immune responses［J］.Front Immunol,2020,11:940.
［4］ LICARETE E,RAUCA VF,LUPUT L,et al.Overcoming intrinsic doxorubicin resistance in melanoma by anti-angiogenic and anti-metastatic effects of liposomal prednisolone phosphate on tumor microenvironment［J］.Int J Mol Sci,2020,21(8):2968.
［5］TIWARI A,TRIVEDI R,LIN SY.Tumor microenvironment:barrier or opportunity towards effective cancer therapy［J］.J Biomed Sci,2022,29(1):83.
［6］ CAMPO E,JAFFE ES,COOK JR,et al.The international consensus classification of mature lymphoid neoplasms:A report from the clinical advisory committee［J］.Blood,2022,140(11):1229-1253.
［7］PULTE D,JANSEN L,BRENNER H.Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century［J］.Blood Cancer J,2020,10(5):56.
［8］ALAGGIO R, AMADOR C,ANAGNOSTOPOULOS I,et al.The 5th edition of the world health organization classification of haematolymphoid tumours:Lymphoid neoplasms［J］.Leukemia,2022,36:1720-1748.
［9］SCOTT DW,GASCOYNE RD.The tumour microenvironment in B cell lymphomas［J］.Nat Rev Cancer,2014,14(8):517-534.
［10］ALIZADEH AA,EISEN MB,DAVIS RE,et al.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling［J］.Nature，2000,403(6769):503-511.
［11］SCOTT DW,WRIGHT GW,WILLIAMS PM,et al.Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue［J］.Blood,2014,123(8):1214-1217.
［12］ WEN R,WANG D.MCD-DLBCL arises from germinal center B cells［J］.Blood，2022,140(10):1058-1059.
［13］ WRIGHT GW,HUANG DW,PHELAN JD,et al.A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications［J］.Cancer Cell,2020,37(4):551-568.
［14］ SCHMITZ R,WRIGHT GW,HUANG DW,et al.Genetics and pathogenesis of diffuse large B-Cell lymphoma［J］.N Engl J Med,2018,378(15):1396-1407.
［15］ROSENWALD A,WRIGHT G,CHAN WC,et al.The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma［J］.N Engl J Med,2002,346(25):1937-1947.
［16］ LENZ G,WRIGHT G,DAVE SS,et al.Stromal gene signatures in large-B-cell lymphomas［J］.N Engl J Med,2008,359(22):2313-2323.
［17］CIAVARELLA S,VEGLIANTE MC,FABBRI M,et al.Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue［J］.Ann Oncol,2018,29(12):2363-2370.
［18］ MANTOVANI A,ALLAVENA P,MARCHESI F,et al.Macrophages as tools and targets in cancer therapy［J］.Nat Rev Drug Discov,2022,21(11):799-820.
［19］XIONG X,XIE X,WANG Z,et al.Tumor-associated macrophages in lymphoma:From mechanisms to therapy［J］.Int Immunopharmacol,2022,112:109235.
［20］ HASSELBLOM S,HANSSON U,SIGURDARDOTTIR M,et al.Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis［J］.Pathol Int,2008,58(8):529-532.
［21］ GHORAB DS,HELALY AM,EL MAHDI HS,et al.Prognostic role of tumor microenvironment in DLBCL and relation to patients' clinical outcome:A clinical and immunohistochemical study［J］.Anal Cell Pathol (Amst),2022,2022:9993496.
［22］ WANG J,GAO K,LEI W,et al.Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma:correlation with CD163 positive M2 type tumor-associated macrophages,not PD-1 positive tumor-infiltrating lymphocytes［J］.Oncotarget,2017,8(3):5414-5425.
［23］CAI QC,LIAO H,LIN SX,et al.High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma［J］.Med Oncol,2012,29(4):2317-2322.
［24］ NAM SJ,GO H,PAIK JH,et al.An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab,cyclophosphamide,doxorubicin,vincristine and prednisone［J］.Leuk Lymphoma,2014,55(11):2466-2476.
［25］ RIIHIJARVI S,FISKVIK I,TASKINEN M,et al.Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma:a correlative study from a Nordic phase II trial［J］.Haematologica,2015,100(2):238-245.
［26］WADA N,ZAKI MA,HORI Y,et al.Tumour-associated macrophages in diffuse large B-cell lymphoma:a study of the Osaka Lymphoma Study Group［J］.Histopathology,2012,60(2):313-319.
［27］ LI YL,SHI ZH,WANG X,et al.Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count［J］.BMC Cancer,2019,19(1):1049.
［28］ ZHU MY,LIU WJ,WANG H,et al.NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization［J］.Cancer Manag Res,2019,11:4577-4595.
［29］ SHEN L,LI H,SHI Y,et al.M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma［J］.Sci Rep,2016,6:30347.
［30］ MEZAWA Y,ORIMO A.Phenotypic heterogeneity,stability and plasticity in tumor-promoting carcinoma-associated fibroblasts［J］.FEBS J,2022,289(9):2429-2447.
［31］ AN Y,LIU F,CHEN Y,et al.Crosstalk between cancer-associated fibroblasts and immune cells in cancer［J］.J Cell Mol Med,2020,24(1):13-24.
［32］ RUAN J,HYJEK E,KERMANI P,et al.Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma［J］.Clin Cancer Res,2006,12(19):5622-5631.
［33］ ABD EL ALL H.Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors:pilot study［J］.Diagn Pathol,2007,2:9.
［34］ SAKAMOTO A,KUNOU S,SHIMADA K,et al.Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells［J］.Cancer Sci,2019,110(1):269-278.
［35］ AOKI T,SHIMADA K,SAKAMOTO A,et al.Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism［J］.Oncotarget,2017,8(8):13085-13098.
［36］APOLLONIO B,SPADA F.Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma［J］.J Clin Invest,2023,e166070.
［37］ BRUMMEL K,EERKENS AL,DE BRUYN M,et al.Tumour-infiltrating lymphocytes:from prognosis to treatment selection［J］.Br J Cancer,2023,128(3):451-458.
［38］ TAY C,TANAKA A,SAKAGUCHI S.Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy［J］.Cancer Cell,2023,41(3):450-465.
［39］ KIMURA S,OSHIRO Y,IWASAKI H,et al.Programmed cell death-ligand 1 (PD-L1)+ tumour cells and low-reacting programmed cell death 1 (PD1)+ tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus+ diffuse large B-cell lymphoma［J］.Clin Exp Med,2022,22(3):411-419.
［40］ MURIS JJ,MEIJER CJ,CILLESSEN SA,et al.Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas［J］.Leukemia,2004,18(3):589-596.
［41］HASSELBLOM S,SIGURDADOTTIR M,HANSSON U,et al.The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma［J］.Br J Haematol,2007,137(4):364-373.
［42］ LOS M,HERR I,FRIESEN C,et al.Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)［J］.Blood,1997,90(8):3118-3129.
［43］ COCK JG,TEPPER AD,VRIES E,et al.Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation［J］.J Biol Chem,1999,274(20):14255-14261.
［44］ COUTINHO R,CLEAR AJ,MAZZOLA E,et al.Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry:robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP［J］.Haematologica,2015,100(3):363-369.
［45］ TZANKOV A,MEIER C,HIRSCHMANN P,et al.Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma,follicular lymphoma and classical Hodgkin's lymphoma［J］.Haematologica,2008,93(2):193-200.
［46］ SU X,SUN T,LI M,et al.Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape［J］.J Transl Med,2022,20(1):378.
［47］ CHEN BJ,DASHNAMOORTHY R,GALERA P,et al.The immune checkpoint molecules PD-1,PD-L1,TIM-3 and LAG-3 in diffuse large B-cell lymphoma［J］.Oncotarget,2019,10(21):2030-2040.
［48］ FANG X,XIU B,YANG Z,et al.The expression and clinical relevance of PD-1,PD-L1,and TP63 in patients with diffuse large B-cell lymphoma［J］.Medicine (Baltimore),2017,96(15):e6398.
［49］KWON D,KIM S,KIM PJ,et al.Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas［J］.Histopathology,2016,68(7):1079-1089.
［50］ MCCORD R,BOLEN CR,KOEPPEN H,et al.PD-L1 and tumor-associated macrophages in de novo DLBCL［J］.Blood Advances,2019,3(4):531-540.
［51］AUTIO M,LEIVONEN SK,BRUCK O,et al.Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma［J］.Haematologica,2021,106(3):718-729.
［52］ CHANG KC,HUANG GC,JONES D,et al.Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses［J］.Clin Cancer Res,2007,13(22):6666-6672.
［53］MEYER PN,FU K,GREINER T,et al.The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab［J］.Am J Clin Pathol,2011,135(1):54-61.
［54］ BRANDT S,MONTAGNA C,GEORGIS A,et al.The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma［J］.Exp Hematol Oncol,2013,2(1):27.
［55］冯永怀，吴柳松，苏俊，等.MMP-26、TIMP-4和MMP-9在弥漫大B细胞淋巴瘤中的表达及意义［J］.中国实验血液学杂志，2013,21(5):1167-1172.
FENG YH,WU LS,SU J,et al.Expression and significance of MMP-26,TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells［J］.Chinese Journal of Experimental Hematology,2013,21(5):1167-1172.
［56］ GOUDA HM,KHORSHIED MM,EL SISSY MH,et al.Association between matrix metalloproteinase 2 (MMP2) promoter polymorphisms and the susceptibility to non-Hodgkin's lymphoma in Egyptians［J］.Ann Hematol,2014,93(8):1313-1318.
［57］ MALAPONTE G,HAFSI S,POLESEL J,et al.Tumor microenvironment in diffuse large B-cell lymphoma:Matrixmetalloproteinases activation is mediated by osteopontin overexpression［J］.Biochim Biophys Acta,2016,1863(3):483-489.
［58］ KYLLONEN H,PASANEN AK,KUITTINEN O,et al.Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody［J］.Leuk Lymphoma,2009,50(8):1301-1307.